BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/26/2020 12:01:03 PM | Browse: 619 | Download: 1106
 |
Received |
|
2020-04-29 14:39 |
|
Peer-Review Started |
|
2020-04-29 14:39 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-05-24 21:51 |
|
Revised |
|
2020-06-02 02:21 |
|
Second Decision |
|
2020-09-22 10:59 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-09-22 20:19 |
|
Articles in Press |
|
2020-09-22 20:19 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-10-16 02:37 |
|
Publish the Manuscript Online |
|
2020-10-26 12:01 |
| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Inflammatory bowel disease: Therapeutic limitations and prospective of the stem cell therapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Rangnath Mishra, Punita Dhawan, Anand S Srivastava and Amar B Singh |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Department of Veterans Affairs |
2I01BX002761-05 |
| Department of Veterans Affairs |
2I01BX002086-06A1 |
| The National Institutes of Health |
1R01DK124095-01A1 |
| The National Institutes of Health |
1R21CA216746-01A1 |
|
| Corresponding Author |
Amar B Singh, PhD, Professor, Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, NA, Omaha, NE 68118, United States. amar.singh@unmc.edu |
| Key Words |
Crohn′s disease; Ulcerative colitis; Mesenchymal stem cells; Hematopoietic stem cells; Mucosal healing; |
| Core Tip |
Mucosal healing is gaining acceptance as a measure of the disease activity remission in inflammatory bowel disease (IBD) patients, however, its regulation and means of therapeutic targeting remain unclear. In this article, we elaborate upon stem-cell therapy, which uses hematopoietic or mesenchymal stem cells, as a promising therapeutic option for IBD. The over-reaching concept is that the stem cells can migrate to the damaged areas of the intestine and differentiate into the mature intestinal epithelial cells to restore the barrier integrity of the intestinal lining, and hence, prevent the immunomodulatory induction, the root cause of IBD, and thus patient’s quality of life. |
| Publish Date |
2020-10-26 12:01 |
| Citation |
Mishra R, Dhawan P, Srivastava AS, Singh AB. Inflammatory bowel disease: Therapeutic limitations and prospective of the stem cell therapy. World J Stem Cells 2020; 12(10): 1050-1066 |
| URL |
https://www.wjgnet.com/1948-0210/full/v12/i10/1050.htm |
| DOI |
https://dx.doi.org/10.4252/wjsc.v12.i10.1050 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
